Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nicole Didonato

Physician Assistant Beloit, OH Physician Assistant

NPI 1760909436 CMS profile 10988275

18586 5Th St, Beloit, OH 44609

Open in the dashboard

General payments

$10,324

482 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Didonato of Beloit, OH is reported in the CMS Open Payments database as having received $10,324 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,409 112
2024 General $2,430 107
2023 General $2,272 104
2022 General $1,771 74
2021 General $1,443 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Didonato
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Nicole Didonato were reported at $2,409. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Nicole Didonato Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,443 $132 $37–$438 $132
2022 $1,771 $155 $48–$522 $149
2023 $2,272 $167 $52–$557 $160
2024 $2,430 $178 $55–$600 $164
2025 $2,409 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,933 114 payments
  2. Janssen Biotech, Inc. $1,087 43 payments
  3. Genzyme Corporation $1,011 34 payments
  4. E.R. Squibb & Sons, L.L.C. $730 27 payments
  5. Lilly USA, LLC $669 35 payments
  6. Regeneron Healthcare Solutions, Inc. $550 23 payments
  7. Novartis Pharmaceuticals Corporation $502 30 payments
  8. Sun Pharmaceutical Industries Inc. $480 18 payments
  9. Amgen Inc. $428 24 payments
  10. Galderma Laboratories, L.P. $405 23 payments
  11. Other $2,529 111 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,483 471 payments
  2. Education $841 11 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $1,707 56 payments
  2. TREMFYA $1,148 41 payments
  3. SKYRIZI Immunology $815 52 payments
  4. RINVOQ $643 33 payments
  5. SOTYKTU $596 24 payments
  6. DUPIXENT Inflammation And Immunology $393 14 payments
  7. CIBINQO $374 17 payments
  8. TALTZ $325 17 payments
  9. VTAMA $310 10 payments
  10. SKYRIZI Immunology $279 16 payments
  11. Other $5,305 309 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

421

Median for Physician Assistant: 241

Drug cost

$128,823

Median for Physician Assistant: $4,110

Branded share of claims

7.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 32 $119,968
Clobetasol Propionate Generic 74 $2,687
Metronidazole Generic 19 $1,116
Ketoconazole Generic 73 $994
Desonide Generic 30 $960
Dapsone Generic 24 $793
Triamcinolone Acetonide Generic 63 $610
Doxycycline Monohydrate Generic 29 $552
Clindamycin Phosphate Generic 12 $424
Ammonium Lactate Generic 18 $311

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$36,465

Of which drugs: $335

Medicare patients

260

Average age 72

Services billed

1,106

139 women, 121 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 50%
Diabetes 23%
Ischemic heart disease 20%
Depression 18%
Chronic kidney disease 16%
Cancer 13%
COPD 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 30 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $299
  • Regeneron Healthcare Solutions, Inc. $86
$385 32 —
VTAMA
  • Dermavant Sciences, Inc. $287
$287 — —
TREMFYA
  • Janssen Biotech, Inc. $261
$261 — —
SKYRIZI
  • AbbVie, Inc. $241
$241 — —
RINVOQ
  • AbbVie, Inc. $220
$220 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record